KPTI - Karyopharm Therapeutics upgraded to outperform at RBC on discounted valuation

• RBC Capital Markets has upgraded Karyopharm Therapeutics ( NASDAQ: KPTI ) to outperform from market perform saying the company's opportunities are discounted in the stock price.
• The firm also upped its price target to $10 from $7 (~120% upside based on Thursday's close).
• The stock is up 12% in Friday morning trading.
• Analyst Brian Abrahams highlighted cancer treatment Xpovio (selinexor), which he said could achieve $700M in annual sales based on its activity across multiple tumor types.
• He added that Xpovio could see growth with potential approval in myelofibrosis and endometrial cancer. He sees ~$300M in peak sales for the former indication, and the latter adding ~$140M in revenue.
• Karyopharm's ( KPTI ) Q3 results, released earlier Friday, beat on the top and bottom lines .

For further details see: